Mizuho Maintains Outperform on Apogee Therapeutics, Raises Price Target to $110

Mizuho analyst Joseph Catanzaro maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target from $105 to $110.